Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$1.47 +2.1%	$1.30	$0.99 ▼ $5.17	$159.17M	0.42	1.19 million shs	427,651 shs
IKT Inhibikase Therapeutics	$2.03 -1.0%	$2.01	$1.12 ▼ $4.20	$150.91M	1.01	235,003 shs	95,042 shs
PVCT Provectus Biopharmaceuticals	$0.08 -2.9%	$0.09	$0.04 ▼ $0.18	$32.61M	0.85	203,253 shs	581,797 shs
VYGR Voyager Therapeutics	$3.28 -0.3%	$3.24	$2.65 ▼ $9.55	$181.50M	0.95	461,375 shs	1.37 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	-0.69%	+14.29%	0.00%	-25.39%	+39.81%
IKT Inhibikase Therapeutics	+0.99%	+15.82%	-8.89%	-6.82%	+11.41%
PVCT Provectus Biopharmaceuticals	-6.11%	-8.37%	-12.00%	-23.32%	-53.00%
VYGR Voyager Therapeutics	+20.96%	+12.67%	-9.62%	-16.92%	-60.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRS Aclaris Therapeutics	2.4993 of 5 stars	3.6	1.0	0.0	0.0	2.7	1.7	1.3
IKT Inhibikase Therapeutics	1.2307 of 5 stars	3.3	2.0	0.0	0.0	0.6	0.0	0.6
PVCT Provectus Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	4.7543 of 5 stars	4.6	2.0	0.0	4.6	2.5	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$9.71	560.84% Upside
IKT Inhibikase Therapeutics	2.50	Moderate Buy	$6.50	220.20% Upside
PVCT Provectus Biopharmaceuticals	0.00	N/A	N/A	N/A
VYGR Voyager Therapeutics	3.13	Buy	$13.39	308.23% Upside

Current Analyst Ratings Breakdown

Latest PVCT, ACRS, IKT, and VYGR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	ACRS Aclaris Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$8.00
5/14/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $16.00
5/9/2025	ACRS Aclaris Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$15.00 ➝ $9.00
4/8/2025	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/28/2025	IKT Inhibikase Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/18/2025	ACRS Aclaris Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight
3/13/2025	VYGR Voyager Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00
3/13/2025	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/12/2025	VYGR Voyager Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$12.00 ➝ $10.00
3/12/2025	VYGR Voyager Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
3/12/2025	VYGR Voyager Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight

(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$17.78M	8.95	N/A	N/A	$2.22 per share	0.66
IKT Inhibikase Therapeutics	$260K	580.44	N/A	N/A	$1.78 per share	1.14
PVCT Provectus Biopharmaceuticals	$560K	58.24	N/A	N/A	($0.02) per share	-3.88
VYGR Voyager Therapeutics	$66.96M	2.71	$2.33 per share	1.41	$5.37 per share	0.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$88.48M	-$1.39	N/A	N/A	N/A	-136.65%	-40.26%	-31.71%	8/6/2025 (Estimated)
IKT Inhibikase Therapeutics	-$19.03M	-$2.67	N/A	N/A	N/A	N/A	-350.63%	-201.82%	N/A
PVCT Provectus Biopharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	-418.23%	N/A	-289.35%	8/11/2025 (Estimated)
VYGR Voyager Therapeutics	$132.33M	-$1.46	4.62	N/A	N/A	15.80%	8.33%	6.15%	8/5/2025 (Estimated)

Latest PVCT, ACRS, IKT, and VYGR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2025	Q1 2025	ACRS Aclaris Therapeutics	-$0.19	-$0.12	+$0.07	-$0.12	$3.55 million	N/A
5/6/2025	Q1 2025	VYGR Voyager Therapeutics	-$0.35	-$0.53	-$0.18	-$0.53	$13.55 million	$6.47 million
3/11/2025	Q4 2024	VYGR Voyager Therapeutics	-$0.35	-$0.59	-$0.24	-$0.59	$16.58 million	$4.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
PVCT Provectus Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	7.03	7.03
IKT Inhibikase Therapeutics	N/A	0.85	0.85
PVCT Provectus Biopharmaceuticals	N/A	0.12	0.12
VYGR Voyager Therapeutics	N/A	8.45	8.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
IKT Inhibikase Therapeutics	3.81%
PVCT Provectus Biopharmaceuticals	0.05%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	6.40%
IKT Inhibikase Therapeutics	7.30%
PVCT Provectus Biopharmaceuticals	14.70%
VYGR Voyager Therapeutics	6.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	108.28 million	66.86 million	Optionable
IKT Inhibikase Therapeutics	6	74.34 million	66.18 million	Not Optionable
PVCT Provectus Biopharmaceuticals	4	420.28 million	366.48 million	Not Optionable
VYGR Voyager Therapeutics	100	55.34 million	52.15 million	Optionable

PVCT, ACRS, IKT, and VYGR Headlines

Recent News About These Companies

Voyager Technologies, Inc. Announces Launch of Initial Public Offering

June 3 at 5:51 AM | finanznachrichten.de

Space Firm Voyager Technologies Seeks $1.6 Billion Valuation in IPO

June 2 at 7:49 PM | theinformation.com

2001: A Space Odyssey's balletic waltz to be beamed to Voyager 1

May 27, 2025 | newatlas.com

NASA restarts one of Voyager 1's thrusters after 21 years of inactivity

May 26, 2025 | lemonde.fr

Vestal Point Capital LP Raises Stock Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

May 21, 2025 | marketbeat.com

NASA Engineers Revive Long-Dormant Thrusters on Voyager 1, the Farthest Spacecraft From Earth, in a ‘Miracle Save’

May 21, 2025 | msn.com

Voyager Therapeutics' Role in Biotechnology and Market Trends NASDAQ Composite

May 20, 2025 | kalkinemedia.com

With 46% ownership, Voyager Therapeutics, Inc. (NASDAQ:VYGR) has piqued the interest of institutional investors

May 20, 2025 | uk.finance.yahoo.com

Voyager Technologies files to go public

May 19, 2025 | spacenews.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of "Buy" from Brokerages

May 18, 2025 | marketbeat.com

Voyager reports breakthrough in brain drug delivery

May 17, 2025 | uk.investing.com

Voyager Therapeutics Publishes Data on ALPL's Role in AAV Transport Across the Blood-Brain Barrier

May 15, 2025 | quiverquant.com

Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication

May 15, 2025 | globenewswire.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stake Decreased by Bridgeway Capital Management LLC

May 15, 2025 | marketbeat.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock Position Increased by Dimensional Fund Advisors LP

May 13, 2025 | marketbeat.com

Q2 EPS Forecast for Voyager Therapeutics Reduced by Analyst

May 13, 2025 | marketbeat.com

What is Leerink Partnrs' Forecast for VYGR Q2 Earnings?

May 11, 2025 | marketbeat.com

Wedbush Equities Analysts Boost Earnings Estimates for VYGR

May 11, 2025 | marketbeat.com

Farallon Capital Management LLC Has $14.58 Million Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

May 11, 2025 | marketbeat.com

What is Leerink Partnrs' Forecast for VYGR FY2029 Earnings?

May 10, 2025 | marketbeat.com

Voyager Therapeutics, Inc.: Voyager Reports First Quarter 2025 Financial and Operating Results

May 9, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVCT, ACRS, IKT, and VYGR Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$1.47 +0.03 (+2.08%)

Closing price 04:00 PM Eastern

Extended Trading

$1.45 -0.02 (-1.36%)

As of 04:44 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Inhibikase Therapeutics NYSE:IKT

$2.02 -0.02 (-1.22%)

As of 04:00 PM Eastern

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Provectus Biopharmaceuticals OTCMKTS:PVCT

$0.08 0.00 (-2.88%)

As of 03:32 PM Eastern

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

Voyager Therapeutics NASDAQ:VYGR

$3.28 -0.01 (-0.30%)

Closing price 04:00 PM Eastern

Extended Trading

$3.27 -0.01 (-0.30%)

As of 05:10 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time